Reactive oxygen species in colorectal cancer adjuvant therapies

Yang Zhang; Mengqiu Hao; Xuyang Yang; Su Zhang; Junhong Han; Ziqiang Wang; Hai-Ning Chen

doi:10.1016/j.bbadis.2023.166922

Reactive oxygen species in colorectal cancer adjuvant therapies

Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166922. doi: 10.1016/j.bbadis.2023.166922. Epub 2023 Oct 26.

Authors

Yang Zhang¹, Mengqiu Hao², Xuyang Yang¹, Su Zhang², Junhong Han², Ziqiang Wang³, Hai-Ning Chen⁴

Affiliations

¹ Colorectal Cancer Center and Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
² Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
³ Colorectal Cancer Center and Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: wangziqiang@scu.edu.cn.
⁴ Colorectal Cancer Center and Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: hnchen@scu.edu.cn.

PMID: 37898425
DOI: 10.1016/j.bbadis.2023.166922

Abstract

Colorectal cancer (CRC), a prevalent global malignancy, often necessitates adjuvant therapies such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy to mitigate tumor burden in advanced stages. The efficacy of these therapies is significantly influenced by reactive oxygen species (ROS). Previous research underscores the pivotal role of ROS in gut pathology, targeted therapy, and drug resistance. ROS-mediated CRC adjuvant therapies encompass a myriad of mechanisms, including cell death and proliferation, survival and cell cycle, DNA damage, metabolic reprogramming, and angiogenesis. Preliminary clinical trials have begun to unveil the potential of ROS-manipulating therapy in enhancing CRC adjuvant therapies. This review aims to provide a comprehensive synthesis of studies exploring the role of ROS in CRC adjuvant therapies.

Keywords: Adjuvant therapies; Antioxidant; Colorectal cancer; Oxidative stress; Reactive oxygen species.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Colorectal Neoplasms* / metabolism
Humans
Reactive Oxygen Species / metabolism

Substances

Reactive Oxygen Species